EP1450816A4 - Verfahren zur behandlung von störungen im zusammenhang mit erhöhter cholesterinkonzentration - Google Patents
Verfahren zur behandlung von störungen im zusammenhang mit erhöhter cholesterinkonzentrationInfo
- Publication number
- EP1450816A4 EP1450816A4 EP02802882A EP02802882A EP1450816A4 EP 1450816 A4 EP1450816 A4 EP 1450816A4 EP 02802882 A EP02802882 A EP 02802882A EP 02802882 A EP02802882 A EP 02802882A EP 1450816 A4 EP1450816 A4 EP 1450816A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- high cholesterol
- cholesterol concentration
- disorder related
- treating disorder
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34802001P | 2001-11-08 | 2001-11-08 | |
US348020P | 2001-11-08 | ||
PCT/US2002/035900 WO2003039480A2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1450816A2 EP1450816A2 (de) | 2004-09-01 |
EP1450816A4 true EP1450816A4 (de) | 2008-02-13 |
Family
ID=23366328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02802882A Withdrawn EP1450816A4 (de) | 2001-11-08 | 2002-11-08 | Verfahren zur behandlung von störungen im zusammenhang mit erhöhter cholesterinkonzentration |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1450816A4 (de) |
JP (1) | JP2005508368A (de) |
CA (1) | CA2466033A1 (de) |
TW (1) | TW200300078A (de) |
WO (1) | WO2003039480A2 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078396B2 (en) | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
CA2585623C (en) | 2004-10-27 | 2012-06-05 | Daiichi Sankyo Company Limited | Ortho-substituted benzene derivatives |
US8129358B2 (en) | 2006-11-13 | 2012-03-06 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
WO2011014661A2 (en) | 2009-07-29 | 2011-02-03 | The University Of Chicago | Liver x receptor agonists |
US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
CA2848212C (en) * | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
BR112015022174B1 (pt) | 2013-03-13 | 2022-07-05 | Sage Therapeutics, Inc | Compostos esteróides neuroativos, sua composição farmacêutica e seu uso |
US20160022701A1 (en) * | 2013-03-13 | 2016-01-28 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JP2016193835A (ja) * | 2013-09-04 | 2016-11-17 | 学校法人常翔学園 | 核内受容体肝臓x受容体アゴニスト |
EP3086793B1 (de) | 2013-12-24 | 2022-05-11 | Virginia Commonwealth University | Verwendung von oxygenierten cholesterinsulfaten (ocs) zur behandlung von nierenstörungen |
US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
ES2884086T3 (es) | 2015-07-06 | 2021-12-10 | Sage Therapeutics Inc | Oxisteroles y sus procedimientos de uso |
PE20180483A1 (es) | 2015-07-06 | 2018-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos |
US10696712B2 (en) | 2015-07-06 | 2020-06-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
RS62222B1 (sr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | 24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda |
AU2017305239C1 (en) | 2016-08-02 | 2022-08-18 | Durect Corporation | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
AU2017337121B2 (en) | 2016-09-30 | 2022-01-27 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as NMDA modulators |
CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
CN110072874B (zh) | 2016-10-18 | 2022-08-12 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1405818A (en) * | 1972-12-06 | 1975-09-10 | Shionogi & Co | 6beta-amino-steroids and the preparation thereof |
WO1994002503A1 (en) * | 1992-07-22 | 1994-02-03 | Enosys S.A. | Bile acid derivative and use thereof in therapy |
WO2000066611A1 (en) * | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
WO2002090375A2 (en) * | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
US4217288A (en) * | 1977-03-24 | 1980-08-12 | Wisconsin Alumni Research Foundation | Anti-vitamin D compounds |
JPS61254599A (ja) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
IL105050A0 (en) * | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
-
2002
- 2002-11-08 JP JP2003541772A patent/JP2005508368A/ja active Pending
- 2002-11-08 TW TW091132850A patent/TW200300078A/zh unknown
- 2002-11-08 WO PCT/US2002/035900 patent/WO2003039480A2/en active Application Filing
- 2002-11-08 EP EP02802882A patent/EP1450816A4/de not_active Withdrawn
- 2002-11-08 CA CA002466033A patent/CA2466033A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1405818A (en) * | 1972-12-06 | 1975-09-10 | Shionogi & Co | 6beta-amino-steroids and the preparation thereof |
WO1994002503A1 (en) * | 1992-07-22 | 1994-02-03 | Enosys S.A. | Bile acid derivative and use thereof in therapy |
WO2000066611A1 (en) * | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
WO2002090375A2 (en) * | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
Non-Patent Citations (5)
Title |
---|
LAFFITTE B A ET AL: "LXRS CONTROL LIPID-INDUCIBLE EXPRESSION OF THE APOLIPOPROTEIN E GENE IN MACROPHAGES AND ADIPOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 2, 16 January 2001 (2001-01-16), pages 507 - 512, XP001097136, ISSN: 0027-8424 * |
SONG C ET AL: "EFFECTS OF SELECTIVE LIVER X RECEPTOR AGONIST ON ATHEROSCLEROSIS PROGRESSION AND REGRESSION OF APOE KNOCK-OUT MICE", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, 23 October 2001 (2001-10-23), pages II329, XP009016063, ISSN: 0009-7322 * |
SONG C ET AL: "Hypolipidemic effects of selective liver X receptor alpha agonists", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 66, no. 9, September 2001 (2001-09-01), pages 673 - 681, XP004304415, ISSN: 0039-128X * |
SONG C ET AL: "SELECTIVE ACTIVATION OF LIVER X RECEPTOR ALPHA BY 6ALPHA-HYDROXY BILE ACIDS AND ANALOGS", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 65, no. 8, 2000, pages 423 - 427, XP000952749, ISSN: 0039-128X * |
SPARKS D L ET AL: "Link between heart disease, cholesterol, and Alzheimer's disease: a review.", MICROSCOPY RESEARCH AND TECHNIQUE 15 AUG 2000, vol. 50, no. 4, 15 August 2000 (2000-08-15), pages 287 - 290, XP002462914, ISSN: 1059-910X * |
Also Published As
Publication number | Publication date |
---|---|
TW200300078A (en) | 2003-05-16 |
JP2005508368A (ja) | 2005-03-31 |
CA2466033A1 (en) | 2003-05-15 |
EP1450816A2 (de) | 2004-09-01 |
WO2003039480A3 (en) | 2003-06-19 |
WO2003039480A2 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1450816A4 (de) | Verfahren zur behandlung von störungen im zusammenhang mit erhöhter cholesterinkonzentration | |
GB0014969D0 (en) | Novel method of treatment | |
AU2003283958A8 (en) | Method of treating tremors | |
EP1405933A4 (de) | Behandlungslösung zur oberflächenbehandlung von metall und oberflächenbehandlungsverfahren | |
AU2003226301A8 (en) | Method of treating cancer | |
EP1393708A4 (de) | Verfahren zur behandlung von haaren | |
AU2003256847A8 (en) | Method of treating cancer | |
EP1677794A4 (de) | Verfahren zur behandlung einer erkrankung | |
ZA200409331B (en) | Method of treating diabetes | |
IL158439A0 (en) | Method of treating atmospheric pollutants | |
AU2002365814A8 (en) | Method of treating asthma | |
EP1282411A4 (de) | Methode zur behandlung von krebs | |
EP1389105A4 (de) | Behandlungsverfahren | |
GB0112216D0 (en) | Method of treatment | |
GB2369675B (en) | Method of treating biological specimens | |
GB2368397B (en) | Method of treating biological specimens | |
GB0118892D0 (en) | Method of treatment | |
GB2370115B (en) | Method of treating biological specimens | |
GB2370635B (en) | Method of treating biological specimens | |
GB0008921D0 (en) | Method of treatment | |
EP1389129A4 (de) | Verfahren zur behandlung von atemwegserkrankungen | |
GB2381312B (en) | Methods relating to treatment of atherosclerosis | |
EP1604748A4 (de) | Verfahren zur behandlung von abfallglas | |
EP1423118A4 (de) | Verfahren und zusammensetzung für die krebsbehandlung | |
IL161630A0 (en) | Methods of treating endometreosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040604 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SONG, CHING Inventor name: LIAO, SHUTSUNG |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20071219BHEP Ipc: A61P 9/10 20060101ALI20071219BHEP Ipc: A61P 3/06 20060101ALI20071219BHEP Ipc: A61K 31/575 20060101AFI20071219BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080114 |
|
17Q | First examination report despatched |
Effective date: 20090206 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090818 |